Psoriasis and Psoriatic Arthritis

Summary

This Kalorama Information report focuses on current and emerging immunomodulators for cancer. The report covers both current and emerging cancer immunomodulators in detail.

The report includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development are profiled. These include bladder, breast, colorectal, head/neck, kidney, lung, ovarian, pancreatic, and prostate cancers, as well as leukemia, lymphoma, melanoma, multiple myeloma, and neuroblastoma.

The current market segment provides an overview, descriptions of products on the market, market estimates and forecasts, and competitive analysis of leading providers. The emerging market segment provides an overview, descriptions of products in development, market forecasts, and forecasted competitive analysis for 2008. The report also includes current issues and trends affecting the industry.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers' level. The base year for data was 2003. Historical data was provided for the years 2001 and 2002, with forecast data provided for 2004 through 2008. Compound annual growth rates (CAGRs) are provided for the 2001-2003, 2003-2008 and 2001-2008 periods for each industry segment covered. Competitive analysis is provided for the year 2003 for the current market and projected competitive analysis for 2008 for the emerging market. The projected competitive analysis for 2008 was based on products in late stage development, probability of approval and marketing, and demographic trends.

Contents

Chapter One: Executive Summary

Overview
Types
Scope and Methodology
Market Analysis
Trends and Considerations

CHAPTER Two: Pathology and Epidemiology

Overview
- Tumor Necrosis Factor
- Contributing Factors
- National Psoriasis Foundation Survey
- Daily Life Impacts
- Problems Receiving Services Due to Perception of Their Disease
- Quality of Life

Pathology of Psoriasis
- Types
- Plaque Psoriasis
- Guttate Psoriasis
- Inverse Psoriasis
- Pustular Psoriasis
- Erythrodermic Psoriasis
- Types by Location
- Scalp Psoriasis
- Types by Severity

Pathology of Psoriatic Arthritis
The Genetics of Psoriasis and Psoriatic Arthritis
Psoriasis and Psoriatic Arthritis Epidemiology

CHAPTER Three: Current Therapies

Topical Therapy
- Anthralin
- Calcipotriene
- Coal Tar
- Salicylic Acid
- Corticosteroids (Steroids)
- Vitamin A
- Sunlight and Water (Climatotherapy)

Phototherapy
- UV-B Therapy
- PUVA

Systemic Treatments
- Corticosteroids
- Cyclosporine
- Methotrexate
- Retinoids
- Aspirin and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Biological DMARDS
- T-Cell Agents
- Monoclonal TNF Antibodies
- Soluble TNF Receptor Inhibitors

New Developments
Alternative Therapies
- Acupuncture
- Ayurvedic Medicine
- Chinese Medicine
- Chiropractic
- Homeopathic Medicine
- Naturopathic Medicine
- Glucosamine and Chondroitin
- Methylsulfonylmethane (MSM)
- S-adenosylmethionine (SAM-e)
- Magnetic Therapy

CHAPTER Four: Market Analysis

Forecasting Challenges
Market Size and Cost of Treatment
Total Available Market vs Serviceable Available Market
Competition

CHAPTER Five: Company Profiles

Amgen
Angiotech Pharmaceuticals
Biogen IDEC
Centocor, Inc.
Galderma Laboratories
Isis Pharmaceuticals, Inc.
Isotechnika, Inc.
Ligand Pharmaceuticals
Vertex Pharmaceuticals

CHAPTER Six: Conclusions and Strategic Implications

First Conclusion
Implications:
Second Conclusion
Implications:
Third Conclusion
Implications:
Fourth Conclusion
Implications:
Fifth Conclusion
Implications:
Sixth Conclusion
Implications:
Seventh Conclusion
Implications:
Eighth Conclusion
Implications:
Appendix: Company Directory

List of Exhibits

Chapter One: Executive Summary
Table 1-1: Prevalence of Psoriasis and Psoriatic Arthritis in the United
States 2006-2016
Figure 1-1: Distribution of Psoriasis Cases in the United States by Severity: 2006
Table 1-2: Common Psoriasis Treatments
Table 1-3: The Total Available Market for Psoriasis and Psoriatic Arthritis Therapeutics in the United States by Severity 2006-2016
Figure 1-2: Trending in the Total Available Market (TAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States: 2006-2016
Table 1-4: Serviceable Available Market (SAM) for Psoriasis and Psoriatic
Arthritis Therapeutics in the United States by Severity 2006-2016
Figure 4-3: Trending in the Serviceable Available Market (SAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States: 2006-2016

CHAPTER Two: Pathology and Epidemiology
Table 2-1: Types of Psoriasis and Their Characteristics
Table 2-2: Psoriasis Assessment Methods
Table 2-3: Type of Psoriatic Arthritis (PsA) and Their Characteristics
Table 2-4: Prevalence of Psoriasis and Psoriatic Arthritis in the United States by Type 2006-2016
Figure 2-1: Prevalence of Psoriasis, by Severity, in the United States 2006-2016
Figure 2-2: Prevalence of Psoriasis and Psoriatic Arthritis in the United
States 2006-2016

CHAPTER Three: Current Therapies
Table 3-1: Psoriasis and Psoriatic Arthritis Therapeutics and Treatment
Products
Table 3-2: The Psoriasis Treatment Ladder
Table 3-3: Steroid Potency Classes and Products
Table 3-4: Phototherapy Skin Types
Table 3-5: Phototherapy Equipment Manufacturers
Table 3-6: Comparison of Biological Therapeutics for Psoriasis and Psoriatic Arthritis
Table 3-7: Treatments in Development for Psoriasis and Psoriatic Arthritis

CHAPTER Four: Market Analysis
Table 4-1: Total Available Market (TAM) for Psoriasis (by Severity) and
Psoriatic Arthritis Therapeutics in the United States 2006-2016
Figure 4-1: Trending in the Total Available Market (TAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States: 2006-2016
Figure 4-2: Composition of the Total Available Market (TAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States: 2006-2016
Table 4-2: Estimated Monthly Cost per Patient for the Medicinal Treatment of Psoriasis (by Severity) and Psoriatic Arthritis in the United States 2006-2016
Table 4-3: Serviceable Available Market (SAM) for Psoriasis (by Severity) and Psoriatic Arthritis Therapeutics in the United States: 2006-2016
Figure 4-3: Trending in the Serviceable Available Market (SAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States 2006-2016
Figure 4-4: Composition of the Serviceable Available Market (SAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States 2006-2016
Table 4-4: Active Competitors in Ethical Pharmaceuticals for Psoriasis and Psoriatic Arthritis in the United States
Figure 4-3: Trending in Average Monthly Medicinal Treatment Costs for Psoriasis (by Severity) and Psoriatic Arthritis: 2006-2016